Información del artículo
El Texto completo está disponible en PDF
Bibliografía
[1.]
N. Talal.
Sex steroids hormones and systemic lupus erythematosus.
Arthritis Rheum, 24 (1981), pp. 1054-1057
[2.]
R.G. Lahita.
Sex hormones and systemic lupus erythematosus.
Rheum Dis Clin North Am, 26 (2000), pp. 951-968
[4.]
R.L. Wilder.
Neuroendocrine immune-system interactions and autoimmunity.
Ann Rev Immunol, 13 (1995), pp. 307-338
[5.]
H.O. Besedovsky, A. Del Rey.
Immune neuroendocrine interactions.
Endocr Rev, 17 (1996), pp. 64-107
[6.]
I.C. Chikansa, A.B. Grossman.
Reciprocal interactions between the neuroendocrine and immune systems during inflammation.
Rheum Dis Clin North Am, 26 (2000), pp. 693-711
[7.]
K. Karalis, H. Sano, J. Redwinw, et al.
Autocrine or paracrine inflammatory actions of corticotropin-releasing hormone in vivo.
Science, 254 (1991), pp. 421-423
[8.]
L.J. Jara, C. Gómez-Sánchez, L.R. Espinoza.
Prolactin in primary fibromyalgia and rheumatoid arthritis.
J Rheumatol, 18 (1991), pp. 480-481
[9.]
H. Nagafuchi, N. Suzuki, A. Kaneko, et al.
Prolactin locally produced by synovium infiltrating T lymphocites induces excessive synovial cell functions in patients with rheumatoid arthritis.
J Rheumatol, 26 (1999), pp. 1890-1900
[10.]
K. Melez, W. Boegel, A. Steinberg.
Therapeutic studies in New Zeland mice VII. Successful androgen treatment of NZB/NZW F1 females of different ages.
Arthritis Rheum, 23 (1980), pp. 41
[11.]
R.A. Hazelton, A.B. Mc Druden, R.D. Sturrock, et al.
Hormonal manipulation of the immune response in systemic lupus erythematosus: a drug trial of an anabolic steroid, 19-nortestosterone.
Ann Rheum Dis, 42 (1983), pp. 155
[12.]
A. Bizarro, G. Rodríguez, G. Di Martino, et al.
Influence of testosterone therapy on clinical and immunological features of autoimmunes diseases associated with Klinefelter's syndrome.
J Clin Endocrinol Metab, 64 (1987), pp. 32
[13.]
R.G. Lahita, C. Cheng, C. Monder, C.W. Bardin.
Experience with 19-nortestosterone in the therapy of systemic lupus erythematosus: worsened disease after tratment with 19-nortestosterone in men and lack of improvement in women.
J Rheumatol, 19 (1992), pp. 547
[14.]
P. Inserra, Z. Zhang, S.K. Ardestani, M. Araghi-Niknam, B. Liang, et al.
Modulation of cytokine production by dehydroepiandrosterone (DHEA) plus melatonin (MLT) supplementation of old mice.
Proc Soc Exp Biol Med, 218 (1998), pp. 76-82
[15.]
D.M. Chang, S.J. Chu, H.C. Chen, S.Y. Kuo, J.H. Lai.
Dehydroepiandrosterone supresses interleukin 10 synthesis in women with lupus erythematosus systemic.
Ann Rheum Dis, 63 (2004), pp. 1623-1626
[16.]
J.A. Lucas, S.A. Ahmed, M.L. Casey, P.C. MacDonald.
Prevention of antibody formation and prolonged survival in NZB/NZW F1 mice fed dehydroisoandrosterone.
J Clin Invest, 75 (1985), pp. 2091
[17.]
R.F. Van Vollenhoven, E.G. Engleman, J.L. McGuire.
An open study of dehydroepiandrosterone in systemic lupus erythematosus.
Arthritis Rheum, 37 (1994), pp. 1305
[18.]
R. Van Vollenhoven, E. Engleman, J. McGuire.
Dehydroepiandrosterone in systemic lupus erythematosus. Results of a double-blind, placebo-controlled, randomized clinical trial.
Arthritis Rheum, 38 (1995), pp. 1826
[19.]
M. Petri, R. Lahita, J. McGuire, et al.
Results of the GL701 (DHEA) multicenter sterod-sparing SLE study.
Arthritis Rheum, 40 (1997), pp. 327
[20.]
R.F. Van Vollenhoven, J.L. Park, M.C. Genovese, et al.
A double-blind, placebo-controlled, clinical trial of dehydroepiandrosterone in severe systemic lupus erythematosus.
Lupus, 8 (1999), pp. 181
[21.]
R.F. Van Vollenhoven, L.M. Morabito, E.G. Engleman, et al.
Treatment of systemic lupus erythematosus with dehydroepiandrosterone: 50 patients treated up to 12 months.
J Rheumatol, 25 (1998), pp. 285
[22.]
J.T. Merryl.
Dehydrepiandrosterone, a sex steroid metabolite in development for systemic lupus erythematosus.
Expert Opinion Investigational Drugs, 12 (2003), pp. 1017-1025
[23.]
M.A. Petri, P.J. Mease, J.T. Merryl, R.G. Lahita, M.J. Ianini, D.E. Yocum, et al.
Effects of prasterone disease activity and symptoms in women with active systemic lupus erythematosus.
Arthritis Rheum, 50 (2004), pp. 2858-2868
[24.]
R. Derksen.
Dehydroepiandrosterone (DHEA) and systemic lupus erythematosus.
Semin Arthritis Rheum, 27 (1998), pp. 325
[25.]
R. Van Vollenhoven.
Dehydroepiandrosterone in systemic lupus erythematosus.
Rheum Dis Clin North Am, 26 (2000),
[27.]
A.D. Schereiber, P. Chien, A. Tomaski, D.B. Cines.
Effect of danazol in immune thrombocytopenic purpura.
N Engl J Med, 316 (1987), pp. 503
[28.]
R. Mylvaganam, Y.S. Ahn, W.J. Harrington, C.I. Kim.
Immune modulation by danazol in autoimmune thrombocytopenia.
Clin Immunol Immunopathol, 42 (1987), pp. 281
[29.]
R. Mylvaganam, Y.S. Ahn, R.O. García, et al.
Very low dose danazol in idioipathic thrombocytopenic purpura and its role as an immune modulator.
Am J Med Sci, 298 (1989), pp. 215
[30.]
K.M. Connolly, V.J. Stecher, B.W. Snyder, et al.
The effect of danazol in the MRL/lpr mouse model of autoimmune disease.
Agents Actions, 25 (1988), pp. 164
[31.]
K. Pariser, J. Gell, J. Gelfand, et al.
Pilot studies in the use of danazol in the treatment of patients with sytemic lupus erythematosus.
Rev Rhum Mal Osteoartic, 48 (1981), pp. 483
[32.]
K.D. Morley, A. Parke, G.R.V. Hughes.
Systemic lupus erythematosus: two patients treated with danazol.
BMJ, 284 (1982), pp. 1431
[33.]
V. Agnello, K. Pariser, J. Gell, et al.
Preliminary observations on danazol therapy of systemic lupus erythematosus: effects on DNA antibodies, thrombocytopenia and complement.
J Rheumatol, 10 (1983), pp. 682
[34.]
C. Marino, P. Cook.
Danazol for lupus thrombocytopenia.
Arch Intern Med, 145 (1985), pp. 2251
[35.]
S. West, S. Johnson.
Danazol for the treatment of refractory autoimmune thrombocytopenia in systemic lupus erythematosus.
Ann Intern Med, 108 (1988), pp. 703
[36.]
Y. Ahn, W. Harrington, R. Mylvaganam, et al.
Danazol therapy for autoimmune hemolytic anemia.
Ann Inter Med, 102 (1985), pp. 298
[37.]
K.L. Wong.
Danazol in treatment of lupus thrombocytopenia.
Asian Pac J Allergy Immunol, 9 (1991), pp. 125
[38.]
H. Cervera, L.J. Jara, S. Pizarro, et al.
Danazol for SLE with refractory autoimmune thrombocytopenia or Evans syndrome.
J Rheumatol, 22 (1995), pp. 1867
[40.]
M. Dougados, C. Job-Deslandre, B. Amor, C.J. Menkes.
Danazol therapy in systemic lupus erythematosus. A one-year prospective controlled trial on 40 female patients.
Clin Trials J, 24 (1987), pp. 191
[41.]
A. Torrelo, A. Espana, S. Medina, A. Ledo.
Danazol and discoid lupus erythematosus [carta].
Dermatologica, 181 (1990), pp. 239
[42.]
S. Insiripong, T. Chanchairujira, T. Bumpenboon.
Danazol for thrombocytopenia in pregnancy with underlying systemic lupus erythematosus.
J Med Assoc Thai, 79 (1996), pp. 330
[43.]
A.Y. Chan, E.K. Li, L. Tam, G. Cheng, P.C. Choi.
Succesful treatment of pure red cell aplasia associated with systemic lupus erythematosus with oral danazol and steroid.
Rhematol Int, 25 (2005), pp. 388-390
[44.]
C. Arnal, J.C. Piette, J. Leone, B. Taillan, E. Hachula, F. Roudot-Thoraval, et al.
Treatment of severe immune thrombocytopenia associated with systemic lupus erythematosus: 59 cases.
J Rheumatol, 29 (2002), pp. 1-2
[45.]
J.A. Aviña-Zubieta, G. Galindo-Rodríguez, I. Robledo, J. Vela-Ojeda, M. Vadillo-Buenfil, A. Rosas-Cabral, et al.
Long term effectiveness of danazol corticosteroids and citotoxic drugs in the treatment of hematologic manifestation of systemic lupus erythematosus.
Lupus, 12 (2003), pp. 52-57
[46.]
P. Jungers, F. Kuttenn, F. Liote, et al.
Hormonal modulation in systemic lupus erythematosus. Preliminary clinical and hormonal results with cyproterone acetate.
Arthritis Rheum, 28 (1985), pp. 1243-1246
[47.]
P. Jungers, F. Liote, C. Pelissier, et al.
The hormonomodulation in systemic lupus erythematosus: preliminary results with aanazol (D) and cyproterone- acetate (CA).
Ann Med Interne (Paris), 137 (1986), pp. 313
[48.]
G. Mintz, G. Gutiérrez, M. Delezé, E. Rodríguez.
Contraception with progestagens in systemic lupus erythematosus.
Contraception, 30 (1984), pp. 29-31
[49.]
O. Vera, P. Cruz, R. Ariza, et al.
Ovarian function preservation with chlormadinone(CL) in lupus patients receiving cyclophosphamide (CY). A double-blind controlled study.
Arthritis Rheum, 42 (1999), pp. S166
[50.]
Z. Blumenfeld, D. Shapiro, M. Steinberg, et al.
Preservation of fertility and ovarian function and minimizing gonadotoxicity in young women with systemic lupus erythematosus treated by chemotherapy.
Lupus, 9 (2000), pp. 401-405
[51.]
G.E. Katsifis, A.G. Tzioufas.
Ovarian failure in systemic lupus erythematosus patients treated with pulsed intravenous cyclophosphamide.
Lupus, 13 (2004), pp. 673-678
[52.]
Thi Huong L, Wechsler B, Vauthier-Brouzes, Duhat P, Costedoat N, et al. Importance of planning ovulation induction therapy in systemic lupus erythematosus and antiphospholipid syndrome: a single center retrospective study of 21 cases and 114 cycles. Semin Arthritis Rheum. 32:174-88.
[53.]
J.P. Buyon, M.A. Petri, M.Y. Kim, K.C. Kalunian, J. Grossman, B.H. Hahn.
The effect of combined estrogen and progesterone hormone replacement therapy on disease activity in systemic lupus erythematosus: a randomized trial.
Ann Intern Med, 142 (2005), pp. 953-962
[55.]
Z.M. Sthoeger, H. Zinger, E. Mozes.
Beneficial effects of the anti-oestrogen tamoxifen on systemic lupus erythematosus of (NZBxNZW)F1 female mice are associated with specific reduction of IgG3 autoantibodies.
Ann Rheum Dis, 62 (2003), pp. 341-346
[57.]
M.A. Kamal, W.J. Jusko.
Interactions of prednisolone and other immunosuppresants used in dual treatment of systemic lupus erythematosus in lymphocyte proliferation assays.
J Clin Pharmacol, 44 (2004), pp. 1034-1045
[58.]
D. Parkes.
Bromocriptine.
N Engl J Med, 301 (1979), pp. 873
[59.]
R.W. McMurray.
Bromocriptine in rheumatic and autoimmune diseases.
Semin Arthritis Rheum, 31 (2001), pp. 21-32
[60.]
D.J. Petro.
Treatment of systemic lupus erythematosus with bromocriptine.
Lupus, 11 (2002), pp. 266-267
[61.]
S.E. Walker.
Bromocriptine treatment of systemic lupus erythematosus.
Lupus, 10 (2001), pp. 762-768
[62.]
K. Morikawa, F. Oseko, S. Morikawa.
Immunosuppressive activity of bromocriptine on human B-lymphocyte function in vitro.
Clin Exp Immunol, 93 (1993), pp. 200
[63.]
K. Morikawa, F. Oseko, S. Morikawa.
Immunosuppressive activity of bomocriptine on human T lymphocyte function in vitro.
Clin Exp Immunol, 95 (1994), pp. 514
[64.]
R. McMurray, D. Keisler, K. Kanuckel, et al.
Prolactin influences antoimmune disease activity in the female B/W mouse.
J Immunol, 147 (1991), pp. 3780
[65.]
R.W. McMurray, D. Weidensaul, S.H. Allen, S.E. Walker.
Efficacy of bromocriptine in an open label therapeutic trial for systemic lupus erythematosus.
J Rheumatol, 22 (1995), pp. 114
[66.]
E. Peeva, J. Venkatesh, D. Michael, B. Diamond.
Prolactin as a modulator of B cell function: implications for SLE.
Biomed Pharmacother, 58 (2004), pp. 310-319
[67.]
J. Álvarez-Nemegyei, A. Cobarrubias-Cobos, Escalante-Triay, et al.
Bromocriptine in systemic lupus erythematosus: a double-blind, randomized, placebo-controlled study.
Lupus, 7 (1998), pp. 414
[68.]
S.E. Walker, G.H. Reddy, D. Miller, et al.
Treatment of active lupus erythematosus with the prolactin lowering drug, bromocriptine: comparison with hydroxychloroquine in a randomized, blinded one year study.
Arthritis Rheum, 42 (1999), pp. 282
[69.]
S.E. Walker, K.L. Smarr, J.C. Parker, et al.
Moodstates and disease activity in patients lupus erythematosus treated with bromocriptine.
Lupus, 9 (2000), pp. 527-533
[70.]
X.Y. Yang, L.Q. Liang, H.S. Xu, M. He, S.Z. Yao, Z.P. Zhan, et al.
Efficacy of oral bromocriptine in protecting the postpartum systemic lupus erythematosus patients from disease relapse.
Zhonghua Nei Ke Za Zhi, 42 (2003), pp. 621-624
[71.]
A. Hrycek, P. Cieslik, J. Tustanowski, S. Nowak, P. Jedynak.
Selected serum cytokines in systemic lupus erythematosus treated with quinagolide.
Lupus, 10 (2001), pp. 424-430
[72.]
D.S. Singer, L.D. Kohn, H. Zinger, et al.
Methimazole prevents induction of experimental systemic lupus erythematosus in mice.
J Immunol, 153 (1994), pp. 873-880
[73.]
E. Mozes, J. Lovchik, H. Zinger, D.S. Singer.
MHC class I expression regulates susceptibility to spontaneous autoimmune disease in (NZBxNZW)F1 mice.
Lupus, 14 (2005), pp. 308-314
[74.]
L.C. Wang, W.Y. Tsai, Y.H. Yang, B.L. Chiang.
Methimazole-induced lupus erythematosus: a case report.
J Microbiol Immunol Infect, 36 (2003), pp. 278-281
[75.]
P. Harle, G. Pongratz, C. Weidler, R. Buttner, J. Scholmerich, R.H. Straub.
Possible role of leptin in hypoandrogenicity in patients with systemic lupus erythematosus and rheumatoid arthritis.
Ann Rheum Dis, 63 (2004), pp. 809-816
[76.]
H.M. Margolis, P.S. Caplas.
The effect of some steroids (testosterone propionate, desoxycorticosterone acetate ans ascorbic acid and 21-acetoxy (- 5-pregnenolone, artisone acetate) in rheumatoid arthritis.
Ann Intern Med, 34 (1951), pp. 61
[77.]
J.J.F. Belch, R. Madhok, B. McArdle, et al.
Stanozolol as a treatment for rheumatoid arthritis.
Br J Rheumatol, 24 (1985), pp. 102
[78.]
H.A. Bird, L. Burkinshaw, D. Perason, et al.
A controlled trial of nandrolone decanoate in the treatment of rheumatoid arthritis in postmenopausal women.
Ann Rheum Dis, 46 (1987), pp. 237
[79.]
M. Cutolo, E. Balleari, M. Giusti, et al.
Androgen replacement therapy ini male patients with rheumatoid arthritis.
Arthritis Rheum, 34 (1991), pp. 1
[80.]
A. Booij, C.M. Biewenga-Booij, O. Huber-Bruning, et al.
Androgens as adyuvant treatment in postmenopausal female patients with rheumatoid arthritis.
Ann Rheum Dis, 55 (1996), pp. 811
[81.]
G.M. Hall, J.P. Larbre, T.D. Spector, et al.
A randomized trial of testosterone therapy in males with rheumatoide arthritis.
Br J Rheumatol, 35 (1996), pp. 568
[82.]
A.T. Masi, J.A. Da Silva, M. Cutolo.
Perturbations of hypothalamic-pituitary- gonadal (HPG) axis and adrenal androgen (AA) functions in rheumatoid arthritis. Bailliere’.
Clin Rheumatol, 10 (1996), pp. 295-332
[83.]
W.H. Jawes.
Further evidence that low androgen values are a cause of rheumatoid arthritis: the response of rheumatoid arthritis to seriously stressful life events.
Ann Rheum Dis, 56 (1997), pp. 566
[84.]
E.J. Giltay, N.E.E.N. Van der Borden, L.J.G. Gooren, et al.
Androgenizing effects of low-dose cyclosporin in male patients with early RA.
Br J Rheumatol, 37 (1998), pp. 470
[85.]
M. Cutolo, A. Sulli, M. Giusti, et al.
Increase in serum 5(-androstane-3(, 17(-diol glucoronide (3(-diol G) as a possible marker of the androgenmediated immunosuppressive activity exerted by cyclosporin A: preliminary results.
Clin Exp Rheumatol, 12 (1994), pp. 350
[86.]
M. Cutolo, M. Giusti, B. Villaggio, et al.
Testosterone metabolism and cyclosporin A treatment in rheumatoid arthritis.
Br J Rheumatol, 4 (1997), pp. 433
[87.]
M. Cutolo, B. Villaggio, F. Candido, et al.
Antiproliferative and antiinflammatory effects of methotrexate on differentiating myeloid monocytes and synovial macrophages from rheumatoid arthritis patients.
Arthritis Rheum, 43 (1999), pp. 76
[88.]
C. Weidler, S. Struharova, M. Schmidt, B. Ugele, J. Scholmerich, R.H. Straub.
Tumor necrosis factor inhibits conversion of dehydroepiandrosterone sulfate (DHEAS) to DHEA in rheumatoid arthritis synovial cells: a prerequisite for local androgen deficiency.
Arthritis Rheum, 52 (2005), pp. 1721-1729
[89.]
R.H. Straub, G. Pongratz, J. Scholmerich, F. Kees, T.F. Schaible, C. Antoni, et al.
Long-term anti-tumor necrosis factor antibody therapy in rheumatoid arthritis patients sensitizes the pituitary gland and favors adrenal androgen secretion.
Arthritis Rheum, 48 (2003), pp. 1504-1512
[90.]
A.T. Masi, J.W.J. Bijlsma, I.C. Chikanza, C. Pitzalis, M. Cutolo.
Neuroendocrine, immunologic and microvascular systems interactions in rheumatoid arthritis: physiopathogenetic and therapeutic perspectives.
Semin Arthritis Rheum, 29 (1999), pp. 65
[91.]
J.A. Blais.
The use of norethynodrel (Enovid) in the treatment of rheumatoid arthritis.
Arthritis Rheum, 5 (1962), pp. 284
[92.]
H. Waine, E.H. Frieden, H.I. Caplan, T. Cole.
Metabolic effects of Enovid in rheumatoid arthritis.
Arthritis Rheum, 6 (1963), pp. 796
[93.]
M. Gilbert, J. Rotstein, G. Pincus, et al.
Norethynodrel with mestranol in treatment of rheumatoid arthritis.
JAMA, 3 (1964), pp. 235
[94.]
J.W.J. Bijlsma, O. Huber-Bruner, J.H.H. Thijssen.
Effect of oestrogen treatment on clinical and laboratory manifestations of rheumatoid arthritis.
Ann Rheum Dis, 46 (1987), pp. 777
[95.]
J.M.W. Hazes, B.A.C. Dijkmans, J.P. Van den Broucke, A. Cats.
Oral contraceptive treatment for rheumatoid arthritis: an open study in 10 female patients.
Br J Rheumatol, 28 (1989), pp. 28
[96.]
H.R. Van den Brink, A.A. Van Everdingen, M.J.G. Van Wijk, et al.
Adyuvant oestrogen therapy does not improve disease activity in postmenopausal patients with rheumatoid arthritis.
Ann Rheum Dis, 52 (1993), pp. 862
[97.]
G.M. Hall, M. Daniels, E.C. Huskisson, et al.
A randomized controlled trial of the effect of hormone replacement therapy on disease activity in postmenopausal RA.
Ann Rheum Dis, 53 (1994), pp. 112
[98.]
T. Ushiyama, K. Mori, K. Ionoue, et al.
Association of estrogen receptor gene polymorphism with age at onset of rheumatoid arthritis.
Ann Rheum Dis, 58 (1998), pp. 7
[99.]
M. Cutolo, R. Wilder.
Different roles for androgens and estrogens in the susceptibility to autoimmune rheumatic diseases.
Rheum Dis Clin North Am, 26 (2000), pp. 825
[100.]
M. Mitani, Y. Miura, R. Saura, A. Kitagawa, T. Fukuyama, A. Hashiramoto, et al.
Estrogen specifically stimulates expression and production of osteoprotegerin from rheumatoid synovial fibroblasts.
Int J Mol Med, 15 (2005), pp. 827-832
[101.]
R.J. Steffan, E. Matelan, M.A. Ashwell, W.J. Moore, W.R. Solvibile, E. Trybulski, et al.
Synthesis and activity of substituted 4-(indazol-3-yl)phenols as pathway-selective estrogen receptor ligands useful in the treatment of rheumatoid arthritis.
J Med Chem, 47 (2004), pp. 6435-6438
[102.]
M.L. Salem.
Estrogen, a double-edged sword: modulation of TH1- and TH2-mediated inflammations by differential regulation of TH1/TH2 cytokine production.
Curr Drug Targets Inflamm Allergy, 3 (2004), pp. 97-104
[104.]
M.F. Doran, C.S. Crowson, W.M. O’Fallon, S.E. Gabriel.
The effect of oral contraceptives and estrogen replacement therapy on the risk of rheumatoid arthritis: a population based study.
J Rheumatol, 31 (2004), pp. 207-213
[105.]
L.A. Merlino, J.R. Cerhan, L.A. Criswell, T.R. Mikuls, K.G. Saag.
Estrogen and other female reproductive risk factors are not strongly associated with the development of rheumatoid arthritis in elderly women.
Semin Arthritis Rheum, 33 (2003), pp. 72-82
[106.]
H.F. D’Elia, A. Larsen, L.A. Mattsson, E. Waltbrand, G. Kvist, D. Mellstrom, et al.
Influence of hormone replacement therapy on disease progression and bone mineral density in rheumatoid arthritis.
J Rheumatol, 30 (2003), pp. 1456-1463
[107.]
H.F. D’Elia, L.A. Mattsson, C. Ohlsson, E. Nordborg, H. Carlsten.
Hormone replacement therapy in rheumatoid arthritis is associated with lower serum levels of soluble IL-6 receptor and higher insulin-like growth factor 1.
Arthritis Res Ther, 5 (2003), pp. R202-R209
[109.]
A. Al-Mutair, S. Bahabri, S. Al-Mayouf, et al.
Efficacy of recombinant growth hormone in children with juvenile rheumatoid artritis and growth failure.
J Pediatr Endocrinol Metab, 13 (2000), pp. 899-905
[111.]
M.T. Saha, J. Haapasaari, S. Hannula, S. Sarna, H.L. Lenko.
Growth hormone is effective in the treatment of severe growth retardation in children with juvenile chronic arthritis. Doble blind placebo-controlled followup study.
J Rheumatol, 31 (2004), pp. 1413-1417
[112.]
S. Bechtold, P. Ripperger, W. Bonfig, H. Schmidt, H. Bitterling, R. Hafner, et al.
Bone mass development and bone metabolism in juvenile idiopathic arthritis: treatment with growth hormone for 4 years.
J Rheumatol, 31 (2004), pp. 1407-1412
[113.]
D. Simon, N. Lucidarme, A.M. Prieur, J.C. Ruiz, P. Czernichow.
Effects on growth and body composition of growth hormone treatment in children with juvenile idiopathic arthritis requiring steroid therapy.
J Rheumatol, 30 (2003), pp. 2492-2499
[114.]
S. Bechtold, P. Ripperger, R. Hafner, E. Said, H.P. Schwarz.
Growth hormone improves height in patients with juvenile idiopathic arthritis: 4- year data of a controlled study.
J Pediatr, 143 (2003), pp. 512-519
[115.]
L.J.G. Gooren, E.J. Giltay, D. Van Schaardenburg, et al.
Gonadal and adrenal sex steroids in ankylosing spondylitis.
Rheum Dis Clin North Am, 26 (2000), pp. 969-987
[116.]
T.D. Spector, W. Ollier, L.A. Perry, et al.
Free and serum testosterone levels in 276 males: a comparative study of rheumatoid arthritis, ankylosing spondylitis and healthy controls.
Clin Rheumatol, 8 (1989), pp. 7-41
[117.]
E.J. Giltay, C. Popp-Snijders, D. Van Schaardenburg, B.J. Dekker-Saeys, L.J. Gooren, B.A. Dijkmans.
Serum testosterone levels are not elevated in patients with ankylosing spondylitis.
J Rheumatol, 25 (1998), pp. 2389-2394
[118.]
R. Tapia-Serrano, F.J. Jiménez-Balderas, S. Murrieta, et al.
Testicular function in active ankylosing spondylitis. Therapeutic response to human chorionic gonadotrophin.
J Rheumatol, 21 (1991), pp. 1292-1297
[119.]
F.J. Jiménez-Balderas, R. Tapia-Serrano, I. Madero-Cervera, et al.
Ovarian function studies in active ankylosing spondylitis in women. Clinical response to estrogen treatment.
J Rheumatol, 17 (1990), pp. 497-499
[120.]
H. Franck, T. Meurer, L.C. Hofbauer.
Evaluation of bone mineral density, hormones, biochemical markers of bone metabolism, and osteoprotegerin serum levels in patients with ankylosing spondylitis.
J Rheumatol, 31 (2004), pp. 2236-2241
[121.]
N. Miyamoto, M. Mandai, I. Suzuma, K. Suzuma, K. Kobayashi, Y. Honda.
Estrogen protects against cellular infiltration by reducing the expressions of E-selectin and IL-6 in endotoxin-induced uveitis.
J Immunol, 163 (1999), pp. 374-379
[122.]
L.J. Jara, L.H. Silveira, M.L. Cuéllar, et al.
Hyperprolactinemia in Reiter's syndrome.
J Rheumatol, 21 (1994), pp. 1292-1297
Copyright © 2005. Elsevier España S.L. Barcelona
